TY - JOUR
T1 - Post-transplantation cyclophosphamide is associated with increased bacterial infections
AU - Ustun, Celalettin
AU - Chen, Min
AU - Kim, Soyoung
AU - Auletta, Jeffery J.
AU - Batista, Marjorie V.
AU - Battiwalla, Minoo
AU - Cerny, Jan
AU - Gowda, Lohith
AU - Hill, Joshua A.
AU - Liu, Hongtao
AU - Munshi, Pashna N.
AU - Nathan, Sunita
AU - Seftel, Matthew D.
AU - Wingard, John R.
AU - Chemaly, Roy F.
AU - Dandoy, Christopher E.
AU - Perales, Miguel Angel
AU - Riches, Marcie
AU - Papanicolaou, Genovefa A.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2024/1
Y1 - 2024/1
N2 - Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host disease after hematopoietic cell transplantation (HCT); however, it might be associated with more infections. All patients who were ≥2 years old, receiving haploidentical or matched sibling donor (Sib) HCT for acute leukemias or myelodysplastic syndrome, and either calcineurin inhibitor (CNI)- or PTCy-based GVHD prophylaxis [Haploidentical HCT with PTCy (HaploCy), 757; Sibling with PTCy (SibCy), 403; Sibling with CNI-based (SibCNI), 1605] were included. Most bacterial infections occurred within the first 100 days; 953 patients (34.5%) had at least 1 infection and 352 patients (13%) had ≥2 infections. Patients receiving PTCy had a greater incidence of bacterial infections by day 180 [HaploCy 46%; SibCy 48%; SibCNI 35%; p < 0.001]. Compared with the SibCNI without infection cohort, 1.99-fold, 3.33-fold, 2.78-fold, and 2.53-fold increased TRM was seen for the HaploCy cohort without infection and HaploCy, SibCy, and SibCNI cohorts with infection, respectively. Bacterial infections increased mortality [HaploCy (HR1.84, 99% CI: 1.45–2.33, p < 0.0001), SibCy cohort (HR,1.68, 99% CI: 1.30–2.19, p < 0.0001), and SibCNI cohort (HR,1.76, 99% CI: 1.43–2.16, p < 0.0001). PTCy was associated with increased bacterial infections regardless of donor, and bacterial infections were associated with increased mortality irrespective of GVHD prophylaxis. Patients receiving PTCy should be monitored carefully for bacterial infections following PTCy.
AB - Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host disease after hematopoietic cell transplantation (HCT); however, it might be associated with more infections. All patients who were ≥2 years old, receiving haploidentical or matched sibling donor (Sib) HCT for acute leukemias or myelodysplastic syndrome, and either calcineurin inhibitor (CNI)- or PTCy-based GVHD prophylaxis [Haploidentical HCT with PTCy (HaploCy), 757; Sibling with PTCy (SibCy), 403; Sibling with CNI-based (SibCNI), 1605] were included. Most bacterial infections occurred within the first 100 days; 953 patients (34.5%) had at least 1 infection and 352 patients (13%) had ≥2 infections. Patients receiving PTCy had a greater incidence of bacterial infections by day 180 [HaploCy 46%; SibCy 48%; SibCNI 35%; p < 0.001]. Compared with the SibCNI without infection cohort, 1.99-fold, 3.33-fold, 2.78-fold, and 2.53-fold increased TRM was seen for the HaploCy cohort without infection and HaploCy, SibCy, and SibCNI cohorts with infection, respectively. Bacterial infections increased mortality [HaploCy (HR1.84, 99% CI: 1.45–2.33, p < 0.0001), SibCy cohort (HR,1.68, 99% CI: 1.30–2.19, p < 0.0001), and SibCNI cohort (HR,1.76, 99% CI: 1.43–2.16, p < 0.0001). PTCy was associated with increased bacterial infections regardless of donor, and bacterial infections were associated with increased mortality irrespective of GVHD prophylaxis. Patients receiving PTCy should be monitored carefully for bacterial infections following PTCy.
UR - http://www.scopus.com/inward/record.url?scp=85175257429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175257429&partnerID=8YFLogxK
U2 - 10.1038/s41409-023-02131-z
DO - 10.1038/s41409-023-02131-z
M3 - Article
C2 - 37903992
AN - SCOPUS:85175257429
SN - 0268-3369
VL - 59
SP - 76
EP - 84
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 1
ER -